AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment

被引:12
|
作者
Prasad, Kailash [1 ]
机构
[1] Univ Saskatchewan, Coll Med, Dept Anat Physiol & Pharmacol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
关键词
advanced glycation end products; cell receptor for age; soluble RAGE; atrial fibrillation; atrial structural remodeling; atrial electrical remodeling; treatment modalities; GLYCATION-END-PRODUCTS; CELL-ADHESION MOLECULE-1; ENDOGENOUS SECRETORY RAGE; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; SOLUBLE RECEPTOR; HYDROGEN-PEROXIDE; CARDIAC-SURGERY; NADPH OXIDASE; RISK-FACTORS;
D O I
10.1055/s-0039-3400541
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Atrial fibrillation (AF) is the most common of cardiac arrhythmias. Mechanisms such as atrial structural remodeling and electrical remodeling have been implicated in the pathogenesis of AF. The data to date suggest that advanced glycation end products (AGEs) and its cell receptor RAGE (receptor for AGE) and soluble receptor (sRAGE) are involved in the pathogenesis of AF. This review focuses on the role of AGE-RAGE axis in the pathogenesis of AF. Interaction of AGE with RAGE generates reactive oxygen species, cytokines, and vascular cell adhesion molecules. sRAGE is a cytoprotective agent. The data show that serum levels of AGE and sRAGE, and expression of RAGE, are elevated in AF patients. Elevated levels of sRAGE did not protect the development of AF. This might be due to greater elevation of AGE than sRAGE. Measurement of AGE-RAGE stress (AGE/sRAGE) would be appropriate as compared with measurement of AGE or RAGE or sRAGE alone in AF patients. AGE and its interaction with RAGE can induce AF through alteration in cellular protein and extracellular matrix. AGE and its interaction with RAGE induce atrial structural and electrical remodeling. The treatment strategy should be directed toward reduction in AGE levels, suppression of RAGE expression, blocking of binding of AGE to RAGE, and elevation of sRAGE and antioxidants. In conclusion, AGE-RAGE axis is involved in the development of AF through atrial structural and electrical remodeling. The treatment modalities for AF should include lowering of AGE, suppression of RAGE, elevation of sRAGE, and use of antioxidants.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 50 条
  • [31] Physiology and pathophysiology of the atria: Its role in atrial fibrillation
    Godtfredsen, J
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1999, 7 (01) : 13 - 19
  • [32] The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases
    Senatus, Laura M.
    Schmidt, Ann Marie
    FRONTIERS IN GENETICS, 2017, 8
  • [33] Effects of inhibition of AGE-RAGE interaction in pressure-overload hypertrophy by treatment with sRAGE
    Beicu, Catalin F.
    Bradshaw, Amy D.
    Boggs, Janet M.
    Rentz, Tyler J.
    Van Laer, An O.
    Kindy, Mark S.
    Zile, Michael R.
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (06) : S15 - S15
  • [34] Pathophysiology and Treatment Modalities for Atrial Fibrillation: Present and Future
    Prasad, Kailash
    Elefteriades, John A.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 63 - 64
  • [35] An update on atrial fibrillation in 2014: From pathophysiology to treatment
    Ferrari, R.
    Bertini, M.
    Blomstrom-Lundqvist, C.
    Dobrev, D.
    Kirchhof, P.
    Pappone, C.
    Ravens, U.
    Tamargo, J.
    Tavazzi, L.
    Vicedomini, G. G.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 22 - 29
  • [36] Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment
    Markides, V
    Schilling, RJ
    HEART, 2003, 89 (08) : 939 - 943
  • [37] Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
    Weijs, B.
    Schotten, U.
    Crijns, H. J. G. M.
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (05) : 551 - 572
  • [38] Atrial fibrillation - Links between principles of pathophysiology and treatment
    Laszlo, R.
    Graze, H.
    Laszlo, S.
    Schreieck, J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (17) : 862 - 867
  • [39] Biomarkers in Atrial Fibrillation; From Pathophysiology to Diagnosis and Treatment
    Tousoulis, Dimitris
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (05) : 762 - 764
  • [40] Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1
    Arortow, Wilbert S.
    CARDIOLOGY IN REVIEW, 2008, 16 (04) : 181 - 188